Bone turnover in Paget's disease: Biochemical and kinetic measurements during salmon calcitonin therapy

Summary A comparison of calcium-47 kinetics and biochemical measurements has been made in 25 previously untreated patients with Paget's disease. The rate of disappearance of⁴⁷Ca into bone with a turnover time of more than 5 days was measured as A5, and the pool size with a turnover time of less than 5 days as E5. In moderately active disease the reductions in A5 and E5 to be anticipated from treatment seem to be offset by an increase in exchangeability due to remineralization of osteoid. In more active disease the effect of calcitonin may be to shift bone formation from a woven to a lamellar pattern as well as to reduce turnover. Under these circumstances both A5 and E5 are reduced by treatment more in keeping with the biochemical changes.     

Effect of Salmon Calcitonin on Femoral Bone Quality in Adult Ovariectomized Ewes

The aim of this study was to evaluate the effect of intermittent calcitonin on femoral bone quality in adult ewes from the time of ovariectomy. Six months after the start of the experiment, bone density measurements and mechanical testing (torsion and resonant frequency analysis of the diaphysis and compression of an excised trabecular bone cylinder from the femoral neck) were performed in sham-control and ovariectomized (OVX) ewes treated with placebo or salmon calcitonin (50 or 100 units, 3 times/week). Crystallinity of bone was evaluated by measuring X-ray diffraction line broadening. After OVX, a nonsignificant bone loss was found at all measured sites in the femur (−3 to −9%) together with a decreased biomechanical competence in the trabecular bone (compressive strain −28%, P < 0.05). Treatment with salmon calcitonin, 50 or 100 IU subcutaneously three times a week from the time of ovariectomy, resulted in a significant dose-dependent preservation of bone strength in the trabecular bone of the femoral neck compared with OVX. No adverse effects of calcitonin were observed on bone crystal composition as assessed by diffractiometry. We conclude that in adult ewes intermittent calcitonin treatment from the time of OVX was associated with a significant preservation of cancellous bone strength and strain in trabecular bone of the femoral neck, without affecting crystalline properties of bone. Received: 20 October 1995 / Accepted: 19 February 1996     

Early onset of efficacy with fremanezumab in patients with episodic and chronic migraine: subanalysis of two phase 2b/3 trials in Japanese and Korean patients

BackgroundEarly onset of action has become recognized as an important efficacy feature of preventive migraine treatment, which can help overcome adherence issues commonly associated with older medications. Preventive treatments that target the calcitonin gene-related peptide (CGRP) or the CGRP receptor have been previously shown to provide early onset of action.MethodsThis subanalysis of primary endpoints of two separate phase 2b/3 studies sought to determine the onset of action of fremanezumab in Japanese and Korean patients with episodic migraine (EM) and chronic migraine (CM).ResultsIn EM patients (n = 357), both fremanezumab quarterly and fremanezumab monthly led to greater reductions in weekly migraine days (days/week) than placebo from the first week after the initial injection and thereafter during the remainder of the study period. Similarly, CM patients (n = 571) had a greater reduction in headache days of at least moderate severity (days/week) with fremanezumab (total) than placebo. The percentage of patients with a migraine day (EM) or headache day at least moderate severity (CM) was lower in those treated with fremanezumab than placebo and this effect was apparent from as early as Day 2 (1 day after first injection).ConclusionsThese results suggest that fremanezumab has an early onset of action, as noted in previous post hoc analyses of anti-CGRP monoclonal antibodies.Trial registrationClinicalTrials.gov. {"type":"clinical-trial","attrs":{"text":"NCT03303092","term_id":"NCT03303092"}}NCT03303092, Registered 5 October 2017, {"type":"clinical-trial","attrs":{"text":"NCT03303079","term_id":"NCT03303079"}}NCT03303079, Registered 5 October 2017.     

激素对种植体骨结合影响的研究进展

种植体与周围骨形成骨结合对其后期功能的行使、美学的恢复有极其重要的作用.本文着眼于与骨代谢密切相关的激素:糖皮质激素、甲状旁腺激素、降钙素、褪黑素、雌激素,论述激素对种植体骨结合的影响.     

降钙素阴性的甲状腺神经内分泌肿瘤临床病理特征分析

【摘要】 目的 探讨降钙素阴性的甲状腺神经内分泌肿瘤的临床病理特征及鉴别诊断。方法 对1例诊断为降钙素阴性的甲状腺神经内分泌肿瘤病例进行病史收集、形态学检查及免疫表型检测,并复习相关文献。结果 52岁女性患者在我院行甲状腺全切术后,甲状腺右叶剖视见一直径0.6cm的灰白结节,边界欠清,切面实性、质中,镜下肿瘤细胞排列成巢团状,细胞呈卵圆形或梭形,胞浆中等,胞核较小,染色质粗颗粒状,核仁不明显,间质纤维组织增生,免疫表型：甲状腺转录因子1（TTF-1）、嗜铬素A（CgA）、突触素（Syn）和癌胚抗原（CEA）均弥漫阳性,甲状腺球蛋白（TG）、降钙素（CT）均阴性,Ki 67增殖指数<1%。结论 降钙素阴性的神经内分泌肿瘤是一种罕见的甲状腺肿瘤,诊断需结合病理形态尤其是免疫表型。     

儿童荨麻疹合并肺炎的临床特征及预测指标分析

目的 探讨不同严重程度儿童荨麻疹合并肺炎的临床特征及预测指标分析.方法 选取我院2015年4月—2018年4月收治的荨麻疹合并肺炎患儿54例作为荨麻疹并肺炎组,根据荨麻疹活动评分(UAS)分为轻度组、中重度组.选取同期收治的单纯荨麻疹患儿54例作为单纯荨麻疹组.采血检测患儿的血清总免疫球蛋白E(IgE)、降钙素原(PC...     

Effects of Synthetic Salmon Calcitonin on C Cells of the Thyroid

The effects of long term administration of synthetic salmon calcitonin (TZ-CT) on thyroid C cells of rats were evaluated immunohistochemically and electron microscopically. Low dose (0.075, 0.75 and 7.5 IU/kg/day) administration caused no significant changes in the C cell population, whereas high doses (30 and 120 IU kg day) caused C cell suppression. The area ratio of C cells to total cells in the thyroid was measured on sections immunoperoxidase stained for calcitonin. The average C cell ratio was compared among the experimental groups. This mor-phometric analysis of the high-dose and control groups confirmed the differences in C cell populations statistically (30 IU/kg vs. control, pgO.05; 120 IU/kg vs. control, p ≦ 0.05). The suppressive effect of TZ CT on C cells was reversible after cessation of administration for one month. Electron microscopic examination on the C cells in the high dose groups revealed no particular ultrastructural differences. These results may suggest a negative feedback mechanism on C cells by exogenous CT. Acta Pathol Jpn 39: 545-550, 1989.     

降钙素基因相关肽（CGRP）放射免疫检测方法的初步建立

目的；采用国内合成的降钙素基因相关肽（ＣＧＲＰ）及本实验室制备的抗ＣＧＲＰ单克隆抗体建立检测ＣＧＲＰ的放射免疫分析法。方法：酰化试剂法标记ＣＧＲＰ（１－３７），采用平衡饱和加样程序法建立放免分析法。结果：纯化后的标记物计算标记率为３５－４１％，比活度１０００－１２００Ｃｉ／ｍｍｏｌ，放化纯度为９３－９８％，免疫活性〉９２％；该方法的灵敏度为１０－２０ｐｇ／ｍｌ，平均批内及批间变异系数分别为１１．４     

糖尿病患者血浆CGRP RIA

为探讨血浆降钙素基因相关肽含量与糖尿病及其与并发症之间的关系,采用放射免疫分析法测定２８例正常人和６７例非胰岛素依赖型糖尿病患者血浆降钙素基因相关肽水平的变化。结果显示：糖尿病无并发症２血浆降钙素基因相关肽含量较对照组略有些显著意义;伴有并发症各组明显低于对照组伴有并发症者较为无并发症者也显著降低。随着伴有的并发症的增;多,即糖尿病病情的加重,血浆降钙素基因相关肽水平也随之降低。但降钙素基因相关肽     

脑血管病患者CGRP的临床研究

目的：1．观察脑出血（CH）、脑梗死（CI）患者降钙素基因相关肽（CGRP）水平改变及其动态变化;2观察CH、CI病情、病灶大小与CGRP水平变化的关系;3．研究CGRP与脑血管病（CVI））伴发疾病的关系;4．探讨CGRP参与各型CVD及其伴发病中的病理生理机制及其临床意义,并探讨其异常分泌的可能机制;5探讨CVD防治的新途径。方法：选择CVD1I8例,其中CH组46例．CI组62例。用放免法检测血浆CGRP浓度。结果：1．CI组CGRP的变化：显著低于对照组,发病24h内即显著降低,2～3d与4～7d则进一步降低,8～15d开始升高,15d后逐渐升至正常水平。伴发病积分＞6分组显著低于＜6分组,高血糖组显著低于正常血糖组。2．CH组CGRP的变化：显著低于对照组．发病24h内即显著降低,2～3d与4～7d进一步降低,8～15d有所升高,15d后进一步升高,仍低于正常水平。随病情加重,脑出血量增加,CGRP水平明显降低。结论：l．CICH患者存在CBRP分泌异常,CGRP参与了CVD的病理生理过程。2．各组CVD、CGRP动态检测可作为病情严重程度、病灶大小及预后的重要指标。3．本研究结果提示,调整CGRP的分泌将有助于改善各组CVD的预后．并为应用CGRP治疗缺血性脑损伤提供了广阔的前景。